Can targeting the tumor microenvironment enhance therapeutic outcomes?
Yes, targeting components of the TME offers a promising strategy to improve therapeutic outcomes. For example, disrupting the vascular supply to tumors can reduce nutrient availability and enhance the effects of traditional therapies. Inhibiting specific signaling pathways within stromal or immune cells can also restore sensitivity to anticancer drugs. Emerging treatments that modulate the immune landscape of the TME, such as immune checkpoint inhibitors, have shown significant promise in enhancing anti-tumor responses.
